Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.44 [0.11, 1.81]
Studies not reported
Very low
Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.22 [0.03, 1.6]
Studies not reported
Very low
Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher remission for at least 24 weeks compared with placebo (low certainty).
1 finding from 1 review
RR 9.5 [2.3, 39.21]
Studies not reported
Low
Flare‐ups or relapse (continuous) · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 1.78 [0.2, 16.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any withdrawals due to AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 2.7 [0.13, 58.24]
Studies not reported
Very low
Durable remission · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).
1 finding from 1 review
RR 13 [1.75, 96.33]
Studies not reported
Low
Relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab probably leads to lower disease relapse compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.68 [0.53, 0.86]
Studies not reported
Moderate
Disease flare · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 1.03 [0.96, 1.11]
Studies not reported
Low
Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any serious adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.35, 1.28]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any withdrawals due to AEs compared with placebo (low certainty).
1 finding from 1 review
RR 2 [0.19, 21.54]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Incidence of dementia · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · older people with age‐related memory loss
NSAIDs (celecoxib) may leads to higher adverse events – gastrointestinal compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive decline · older people with age‐related memory loss
1 finding from 1 review
Activities of daily living · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found